Hayashi A, Ishihara H, Kawabe M, Kato K, Nakashima A, Yamamoto I
Front Med (Lausanne). 2025; 12:1530804.
PMID: 39958825
PMC: 11826805.
DOI: 10.3389/fmed.2025.1530804.
Yu Q, Li J, Mao W, Li Z, Li X, Li B
Health Sci Rep. 2024; 7(11):e70178.
PMID: 39587995
PMC: 11586633.
DOI: 10.1002/hsr2.70178.
Li L, Li Z, Wang W, Long X, Liu P, Wang G
J Fluoresc. 2024; .
PMID: 39352679
DOI: 10.1007/s10895-024-03960-x.
Zhang Y, Liu J, Lo T, Kim Y, Lucien F, Dong H
Biosens Bioelectron X. 2024; 19.
PMID: 39091597
PMC: 11290324.
DOI: 10.1016/j.biosx.2024.100490.
Zvirble M, Survila Z, Bosas P, Dobrovolskiene N, Mlynska A, Zaleskis G
Front Immunol. 2024; 15:1401097.
PMID: 39055716
PMC: 11269106.
DOI: 10.3389/fimmu.2024.1401097.
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.
Pitts S, Schlom J, Donahue R
J Exp Clin Cancer Res. 2024; 43(1):155.
PMID: 38822401
PMC: 11141022.
DOI: 10.1186/s13046-024-03074-z.
Development of a microcantilever-based biosensor for detecting Programmed Death Ligand 1.
Neairat T, Al-Gawati M, Tul Ain Q, Assaifan A, Alshamsan A, Alarifi A
Saudi Pharm J. 2024; 32(6):102051.
PMID: 38812944
PMC: 11134855.
DOI: 10.1016/j.jsps.2024.102051.
Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.
Kashiwada T, Takano R, Ando F, Kuroda S, Miyabe Y, Owada R
Front Pharmacol. 2024; 15:1384733.
PMID: 38799168
PMC: 11116720.
DOI: 10.3389/fphar.2024.1384733.
Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
Ando F, Kashiwada T, Kuroda S, Fujii T, Takano R, Miyabe Y
Front Pharmacol. 2024; 15:1384731.
PMID: 38774209
PMC: 11106465.
DOI: 10.3389/fphar.2024.1384731.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K
J Clin Invest. 2024; 134(7).
PMID: 38557498
PMC: 10977985.
DOI: 10.1172/JCI168318.
Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies.
Park E, Lee C
Exp Mol Med. 2024; 56(1):100-109.
PMID: 38182653
PMC: 10834419.
DOI: 10.1038/s12276-023-01150-6.
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
Tanizaki J, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A
JTO Clin Res Rep. 2023; 4(12):100590.
PMID: 38029041
PMC: 10679776.
DOI: 10.1016/j.jtocrr.2023.100590.
Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.
Miyazaki S, Fujisue K, Yamanaga K, Sueta D, Usuku H, Tabata N
J Atheroscler Thromb. 2023; 31(4):355-367.
PMID: 37793811
PMC: 10999719.
DOI: 10.5551/jat.64183.
Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients.
Elgohary S, Eissa R, El Tayebi H
Int J Mol Sci. 2023; 24(18).
PMID: 37762557
PMC: 10531892.
DOI: 10.3390/ijms241814254.
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M, Herlea V, Dima S, Sorop A, Pechianu C, Procop A
Gastric Cancer. 2023; 26(6):934-946.
PMID: 37668884
DOI: 10.1007/s10120-023-01429-7.
The predictive role of soluble programmed death ligand 1 in digestive system cancers.
Ruan J, Zhao Z, Qian Y, Xu R, Liao G, Kong F
Front Oncol. 2023; 13:1170220.
PMID: 37519785
PMC: 10374258.
DOI: 10.3389/fonc.2023.1170220.
Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
Ding Y, Sun C, Hu L, Xiong S, Zhai Z
Ann Hematol. 2023; 102(9):2425-2434.
PMID: 37382610
DOI: 10.1007/s00277-023-05325-z.
Regulation of PD-L1 Trafficking from Synthesis to Degradation.
Lemma E, Letian A, Altorki N, McGraw T
Cancer Immunol Res. 2023; 11(7):866-874.
PMID: 37290119
PMC: 10320477.
DOI: 10.1158/2326-6066.CIR-22-0953.
Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells.
Liang Z, Chen W, Guo Y, Ren Y, Tian Y, Cai W
Front Immunol. 2023; 14:1133883.
PMID: 37266424
PMC: 10229872.
DOI: 10.3389/fimmu.2023.1133883.
Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy.
Chiu C, Schou M, McMahon J, Deeks S, Fromentin R, Chomont N
Front Immunol. 2023; 14:1123342.
PMID: 37056754
PMC: 10086427.
DOI: 10.3389/fimmu.2023.1123342.